OBJECTIVE: To follow up on a three-site, 24-week randomized clinical trial (N = 124) comparing antipsychotic medication alone (MED) with antipsychotic medication plus parent training in the behavior management (COMB) of children with autism spectrum disorders and severe behavior problems. The COMB treatment had shown a significant advantage for child behavioral noncompliance (p = .006, d = 0.34), irritability (p = .01, d = 0.48), and hyperactivity/noncompliance (p = .04, d = 0.55) with a lower medication dose. METHOD: One year after each participant's termination, the authors mailed an assessment packet with a return-addressed envelope; a telephone call alerted the family. Failure to return packets within 1 month elicited another contact and offers to resend. RESULTS:Eighty-seven of 124 families (70.2%) participated in the follow-up. The improvement difference between treatments attenuated from after treatment to follow-up for noncompliance (d = 0.32 to 0.12) and irritability (d = 0.46 to 0.03). The follow-up differences were nonsignificant (the noncompliance difference also was nonsignificant after treatment for these 87 families). Sixty-seven percent of the COMB group and 53% of the MED group were still taking risperidone, the original study medication. Most needed dose adjustments or additional medication, and the COMB group no longer had a significantly lower dose. All COMB families but only 39% of MED families reported seeking parent training after treatment. Improvements in daily living skills during treatment predicted noncompliance improvement at follow-up for the COMB children, but noncompliance deterioration and especially hyperactivity/noncompliance deterioration for the MED children. CONCLUSIONS: The study treatment experience/familiarity greatly influenced the follow-up treatment: those who had received parent training reported seeking it, whereas those who had not received it tended not to seek it. The superiority of COMB over MED after treatment attenuated by more than half at follow-up.
RCT Entities:
OBJECTIVE: To follow up on a three-site, 24-week randomized clinical trial (N = 124) comparing antipsychotic medication alone (MED) with antipsychotic medication plus parent training in the behavior management (COMB) of children with autism spectrum disorders and severe behavior problems. The COMB treatment had shown a significant advantage for child behavioral noncompliance (p = .006, d = 0.34), irritability (p = .01, d = 0.48), and hyperactivity/noncompliance (p = .04, d = 0.55) with a lower medication dose. METHOD: One year after each participant's termination, the authors mailed an assessment packet with a return-addressed envelope; a telephone call alerted the family. Failure to return packets within 1 month elicited another contact and offers to resend. RESULTS: Eighty-seven of 124 families (70.2%) participated in the follow-up. The improvement difference between treatments attenuated from after treatment to follow-up for noncompliance (d = 0.32 to 0.12) and irritability (d = 0.46 to 0.03). The follow-up differences were nonsignificant (the noncompliance difference also was nonsignificant after treatment for these 87 families). Sixty-seven percent of the COMB group and 53% of the MED group were still taking risperidone, the original study medication. Most needed dose adjustments or additional medication, and the COMB group no longer had a significantly lower dose. All COMB families but only 39% of MED families reported seeking parent training after treatment. Improvements in daily living skills during treatment predicted noncompliance improvement at follow-up for the COMB children, but noncompliance deterioration and especially hyperactivity/noncompliance deterioration for the MED children. CONCLUSIONS: The study treatment experience/familiarity greatly influenced the follow-up treatment: those who had received parent training reported seeking it, whereas those who had not received it tended not to seek it. The superiority of COMB over MED after treatment attenuated by more than half at follow-up.
Authors: Lawrence Scahill; Christopher J McDougle; Michael G Aman; Cynthia Johnson; Benjamin Handen; Karen Bearss; James Dziura; Eric Butter; Naomi G Swiezy; L Eugene Arnold; Kimberly A Stigler; Denis D Sukhodolsky; Luc Lecavalier; Stacie L Pozdol; Roumen Nikolov; Jill A Hollway; Patricia Korzekwa; Allison Gavaletz; Arlene E Kohn; Kathleen Koenig; Stacie Grinnon; James A Mulick; Sunkyung Yu; Benedetto Vitiello Journal: J Am Acad Child Adolesc Psychiatry Date: 2011-12-23 Impact factor: 8.829
Authors: M Chowdhury; M G Aman; L Scahill; N Swiezy; L E Arnold; L Lecavalier; C Johnson; B Handen; K Stigler; K Bearss; D Sukhodolsky; C J McDougle Journal: J Intellect Disabil Res Date: 2010-03
Authors: Peter S Jensen; L Eugene Arnold; James M Swanson; Benedetto Vitiello; Howard B Abikoff; Laurence L Greenhill; Lily Hechtman; Stephen P Hinshaw; William E Pelham; Karen C Wells; C Keith Conners; Glen R Elliott; Jeffery N Epstein; Betsy Hoza; John S March; Brooke S G Molina; Jeffrey H Newcorn; Joanne B Severe; Timothy Wigal; Robert D Gibbons; Kwan Hur Journal: J Am Acad Child Adolesc Psychiatry Date: 2007-08 Impact factor: 8.829
Authors: Michael G Aman; Christopher J McDougle; Lawrence Scahill; Benjamin Handen; L Eugene Arnold; Cynthia Johnson; Kimberly A Stigler; Karen Bearss; Eric Butter; Naomi B Swiezy; Denis D Sukhodolsky; Yaser Ramadan; Stacie L Pozdol; Roumen Nikolov; Luc Lecavalier; Arlene E Kohn; Kathleen Koenig; Jill A Hollway; Patricia Korzekwa; Allison Gavaletz; James A Mulick; Kristy L Hall; James Dziura; Louise Ritz; Stacie Trollinger; Sunkyung Yu; Benedetto Vitiello; Ann Wagner Journal: J Am Acad Child Adolesc Psychiatry Date: 2009-12 Impact factor: 8.829